Floatz logo

Zi-Ma4-1

Synovial Sarcomas

Zelluna Immunotherapy ASCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Synovial Sarcomas cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Cyclophosphamide
Zelluna Immunotherapy AS
Phase 2BB
Pembrolizumab
Valo Therapeutics Oy
Phase 2B
Cixutumumab
National Cancer Institute (NCI)
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B

View all 36 →

Same molecule, other indications

Zi-Ma4-1 is also rated in:

non-small cell squamous lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
head and neck cancerDormant
C
Indicative ·
39 / 100
View asset →
ovarian cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →